Aortic Valve Surgery for Elderly Patients (80+).
Aortic stenosis is overwhelmingly a disease of aging, and the question of whether to pursue valve intervention in patients over 80 has been transformed by the advent of transcatheter aortic valve replacement (TAVR). Before TAVR, many elderly patients with severe aortic stenosis were told they were "too old" for surgery and managed with medications alone — a strategy that carries a grim prognosis, with median survival of 2 to 3 years after symptom onset. Today, TAVR offers a minimally invasive alternative that avoids sternotomy and cardiopulmonary bypass, dramatically reducing the procedural stress on elderly patients. However, the decision between TAVR, surgical aortic valve replacement (SAVR), and conservative management is more nuanced than many patients realize. Frailty, cognitive function, life expectancy, and valve durability all factor into the optimal choice. For patients in their 80s and beyond, the conversation should focus not just on procedural risk but on the quality of the years gained. A successful valve intervention can transform a homebound, breathless patient into an active, independent person — but only if the right procedure is chosen for the right patient.
What the evidence shows.
The PARTNER trials (1, 2, 3, and their long-term follow-up studies) established TAVR as the standard of care for high-risk and inoperable elderly patients. PARTNER 1 showed that in inoperable patients, TAVR reduced 1-year mortality from 50.7% (medical therapy) to 30.7%. In high-risk surgical candidates, TAVR was non-inferior to SAVR at 5 years. The PARTNER 3 trial, which included lower-risk patients (average age 73), showed TAVR superiority at 1 year, though the advantage narrowed at 5-year follow-up with higher rates of paravalvular leak and pacemaker implantation in the TAVR group. For octogenarians specifically, observational data from the STS/ACC TVT Registry (over 300,000 TAVR procedures) shows 30-day mortality of approximately 3-4% and 1-year mortality of 15-20%, with functional improvement in the majority of survivors.
Current recommendations.
Current guidelines recommend TAVR as the preferred approach for patients over 80 with severe symptomatic aortic stenosis who are at high or extreme surgical risk. For patients over 80 who are at intermediate surgical risk, TAVR is also generally preferred due to faster recovery and comparable intermediate-term outcomes. SAVR may still be preferred in octogenarians who have other cardiac conditions requiring surgery (e.g., concurrent CABG or mitral valve disease) or who have anatomic features unfavorable for TAVR (bicuspid valve, small annulus, peripheral vascular disease limiting access). Shared decision-making with a Heart Team — including a cardiac surgeon, interventional cardiologist, and imaging specialist — is the guideline-mandated approach.
Why this matters for your decision.
Age alone should never be the reason to deny a patient valve intervention. The key question is not "how old is the patient?" but "what is the patient's biological age, functional status, and life expectancy?" An active, independent 85-year-old may benefit enormously from TAVR, while a frail 78-year-old with multiple comorbidities may not. A second opinion ensures that the decision is based on a comprehensive assessment of the individual patient, not a reflexive age-based judgment in either direction.
Need help with this decision?
Our Heart Team evaluates your specific situation with AI-augmented analysis and dual-physician review.